Results 61 to 70 of about 1,009 (151)

Venetoclax combined with azacitidine in blastic plasmacytoid dendritic cell neoplasm: a case report and comprehensive review on the current and future treatment

Frontiers in Medicine
Blastic plasmacytoid dendritic cell neoplasm (BPDCN) is an extremely rare hematological malignancy with a highly aggressive behavior and median survival of <2 years. Especially, most BPDCN patients present with extensive and non-specific skin lesions,
Xiaoning Wang, Xiaoning Wang, Jiashuo Guo, Jiashuo Guo, Yan Liu, Na Zheng, Shaohan Xu, Shaohan Xu, Lianhui Wu, Ruirui Yuan, Liying Xue, Jie Li   +11 more
doaj   +1 more source

Pathology Quiz Case: Plasmacytoid Dendritic Cell Neoplasm

Allergy & Rhinology, 2014
Blastic plasmacytoid dendritic cell neoplasm (BPDCN) is a rare hematologic malignancy that possesses a heterogenous clinical and immunophenotypic presentation. The current case report describes an interesting and unique presentation of BPDCN as a primary
Quinn A. Dunlap B.S., Kristine E. Day M.D., Samuel G. Borak M.D., Bradford A. Woodworth M.D.   +3 more
doaj   +1 more source

First pediatric experience of SL-401, a CD123-targeted therapy, in patients with blastic plasmacytoid dendritic cell neoplasm: report of three cases

Journal of Hematology & Oncology, 2018
Background Blastic plasmacytoid dendritic cell neoplasm (BPDCN) is a highly aggressive hematological malignancy with extremely poor outcome. The median overall survival for adult patients is 9–13 months.
Weili Sun, Huaying Liu, Young Kim, Nicole Karras, Anna Pawlowska, Debbie Toomey, Wade Kyono, Paul Gaynon, Joseph Rosenthal, Anthony Stein   +9 more
doaj   +1 more source

Targeting the alpha subunit of IL-3 receptor (CD123) in patients with acute leukemia

Human Vaccines & Immunotherapeutics, 2020
The IL-3 alpha chain receptor (CD123) is a cell surface protein that is widely expressed by various subtypes of acute leukemia, including acute myeloid leukemia (AML), acute lymphoblastic leukemia and blastic plasmacytoid dendritic cell neoplasm. Notably,
Ibrahim Aldoss, Mary Clark, Joo Y Song, Vinod Pullarkat   +3 more
doaj   +1 more source

Effects of a Low Versus Moderate–High Intense Exercise Program on Innate Immune Recovery, Fitness, and Quality of Life During Pediatric Allo‐HSCT—The ANIMAL Exploratory Randomized Controlled Trial

Pediatric Blood &Cancer, Volume 72, Issue 8, August 2025.
ABSTRACT Objectives Pediatric cancer patients undergoing allogeneic hematopoietic stem cell transplantation (allo‐HSCT) are severely immunosuppressed leading to a high risk for life‐threatening infections. This trial investigates the effects of exercise during allo‐HSCT on immune cell recovery and patient‐related outcomes (DRKS00019865). Methods Twenty‐
Ronja Beller, Sabrina B. Bennstein, Dirk Reinhardt, Gabriele Gauß, Carolina Chamorra Vina, Helmut Hanenberg, Markus Uhrberg, Miriam Götte   +7 more
wiley   +1 more source

Characterization of CD56+ dendritic-like cells: a normal counterpart of blastic plasmacytoid dendritic cell neoplasm? [PDF]

PLoS ONE, 2013
Blastic plasmacytoid dendritic cell neoplasm (BPDCN) is a rare hematological malignancy. Plasmacytoid DCs (pDCs), which are defined as lineage marker (Lin)(-)HLA-DR(+)CD56(-)CD123(+)CD11c(-) cells, are considered to be the normal counterpart of BPDCNs ...
Yohei Osaki, Akihiko Yokohama, Akio Saito, Kenichi Tahara, Kunio Yanagisawa, Yoshiyuki Ogawa, Takuma Ishizaki, Takeki Mitsui, Hiromi Koiso, Makiko Takizawa, Hideki Uchiumi, Takayuki Saitoh, Hiroshi Handa, Hirokazu Murakami, Norifumi Tsukamoto, Yoshihisa Nojima   +15 more
doaj   +1 more source

Clinical management of CMML—State of the art

British Journal of Haematology, Volume 207, Issue 2, Page 350-364, August 2025.
Patients with chronic myelomonocytic leukaemia (CMML) typically present with clinical feature including splenomegaly, constitutional symptoms and autoimmune phenomena, as well as with pathological blood counts and biological features in the marrow. These characteristics may influence the assignment to prognostic categories such as the CPSSmol and also ...
K. Nachtkamp, F. Schulz, N. Gattermann, U. Germing   +3 more
wiley   +1 more source

Evaluation of diagnostic efficacy of NRP‐1/CD304 in hematological diseases

Cancer Medicine, 2023
Background Previous studies had explored the diagnostic or prognostic value of NRP‐1/CD304 in blastic plasmacytoid dendritic cell neoplasm (BPDCN), acute myeloid leukemia (AML), and B‐cell acute lymphoblastic leukemia (B‐ALL), whereas the expression and ...
Yi‐jun Liu, Xiao‐hui Li, Yi‐ling Song, Yi‐chen Zhou, Rong‐zeng Cai, Pei‐dong Chi   +5 more
doaj   +1 more source

眼巩膜受侵母细胞性浆细胞样树突状细胞肿瘤1例并文献复习

Zhongguo shiyan zhenduanxue, 2017
母细胞性浆细胞样树突状细胞肿瘤（blastic plasmacytoid dendritic cell neoplasm,BPDCN）是一种罕见的血液系统恶性肿瘤,易侵犯皮肤和骨髓,目前的诊断还没有完全特征性的指标,治疗上亦无标准有效的治疗手段。BPDCN的发病以老年人居多,现总结我科收治的1例青年男性BPDCN患者临床资料,并结合国内外报道的BPDCN病例,回顾性分析患者的临床特征,提高临床医生对BPDCN的诊疗水平。1病例资料患者,男性,25岁 ...
刘芳, 朱耿军, 任立参, 沈卫章, 赵岩, 徐文   +5 more
doaj  

Efficacy and Safety of Combining r‐ATG With PTCy for GvHD Prophylaxis in Haploidentical HSC Transplantation for Malignancies—A Systematic Review

Journal of Cellular and Molecular Medicine, Volume 29, Issue 11, June 2025.
ABSTRACT Allogeneic haematopoietic stem cell transplantation (HSCT) for haematological malignancies can cause acute and chronic graft‐versus‐host disease (GvHD), impacting graft success and mortality. Rabbit anti‐thymocyte globulin (r‐ATG) or post‐transplant cyclophosphamide (PTCy) is effective in reducing GvHD in haploidentical‐HSCT.
Joseph M. John, Uday Kulkarni, Dinesh Pendharkar, Sachin Jadhav   +3 more
wiley   +1 more source